Latest Breaking News On - Patients with relapsed or refractory solid tumors - Page 1 : comparemela.com

Investigators are aiming to add another agent to the treatment armamentarium for patients with relapsed or refractory solid tumors, as well as those with non-Hodgkin lymphoma, with the development of KB-0742, a CDK9 inhibitor.

United statesMiguel villalona caleroKronos bioNational cancer instituteAmerican association for cancer researchDevelopmental cancer therapeutics programEarly phase therapeutics programMedical oncologyTherapeutics researchAmerican associationCancer researchAccessed mayPatients with relapsed or refractory solid tumorsNon hodgkin lymphomaKb 0742City of hope